Core B: PDX/Biospecimen Core
核心 B:PDX/生物样本核心
基本信息
- 批准号:10576943
- 负责人:
- 金额:$ 17.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-24 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcetatesAndrogen ReceptorAutopsyBiological Specimen BanksCancer Research ProjectCell LineClinicClinicalClinical DataClinical TrialsCollaborationsConfidentiality of Patient InformationDNADataDatabasesEnsureEvaluationFoundationsFreezingFundingGenitourinary systemGrantHistologicHistologyImmunoassayIn Situ HybridizationIn VitroIndividualIndustryInformation DisseminationInfrastructureInstitutionInstitutional Review BoardsInternationalInterventionLaboratoriesMalignant neoplasm of prostateMeasuresMetastatic Neoplasm to the BoneMinorityModelingOperative Surgical ProceduresOrganoidsParaffin EmbeddingPathologicPathologistPathologyPatientsPerformancePhenotypePlasmaPreclinical TestingProcessProductionProgram EfficiencyQuality ControlRNARadical ProstatectomyRecording of previous eventsReproducibilityResearchResearch PersonnelResistanceResourcesRunningSamplingSerumServicesSignal TransductionSpecimenStainsStandardizationSystemTissue MicroarrayTissuesTranslational ResearchUnited States National Institutes of HealthUrineWorkXenograft procedureabirateronebiobankcastration resistant prostate cancercompliance behaviorcostdesignenzalutamideexperienceimprovedminority patientpatient derived xenograft modelpre-clinicalpreclinical studyprogramsquality assurancerelational databaserepositoryroutine caresample collectiontumortumor xenografturologicuser-friendly
项目摘要
The PDX/Biospecimen Core B provides part of the infrastructure support for the P01 Projects. It
has been designed to meet the needs of these projects and serve as a stand-alone resource for
collaborative efforts. The Core B will provide a well-organized and standardized system of
specimen collection, storage, distribution and related clinical/research information
dissemination. There will be consistency and quality assurance in the pathological analysis of
tissue specimens. Specimens from our repository, our LuCaP prostate cancer PDXs and clinical
specimens, particularly those from our rapid autopsy program (e.g. prostate cancer bone
metastases) have been and will continue to be distributed to other prostate cancer investigators
on a national and international basis. The Core B Specific Aims are: 1) Maintain and Distribute
Patient-Derived Prostate Cancer Xenografts, 2) Collect and Distribute Clinical Biopecimens (i.e.
tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine),
processing, quality control, storage, distribution and database entry, 3) Establish and Maintain
Specimen Quality and Core B Service Efficiency Programs, 4) Provide Specialized Pathology
and Laboratory Services, including production of tissue microarrays, interpretation of
immunohistology by urologic pathologists, production of specimen derivatives and perform PSA
immunoassays for research, 5) Administrative Program to obtain samples from minorities,
prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB
requirements, and continually improve quality control measures.
PDX/Biospecimen核心B为P01项目提供部分基础设施支持。它
专为满足这些项目的需求而设计,并作为
合作努力。核心B将提供一个组织良好和标准化的系统
标本收集、储存、分发和相关的临床/研究信息
传播。在病理分析中将有一致性和质量保证
组织标本。样本来自我们的存储库,我们的LuCaP前列腺癌PDX和临床
样本,特别是来自我们快速尸检计划的样本(例如前列腺癌骨骼
转移)已经并将继续分发给其他前列腺癌研究人员
在国家和国际基础上。核心B的具体目标是:1)维护和分发
患者来源的前列腺癌异种移植,2)收集和分发临床生物制剂(即
组织,包括手术和快速尸检程序中的组织,血清、血浆和尿液),
加工、质量控制、储存、配送和数据库录入,3)建立和维护
标本质量和核心B服务效率计划,4)提供专门的病理学
和实验室服务,包括组织微阵列的生产、解释
泌尿外科病理学家的免疫组织学,标本衍生品的制作和PSA的执行
用于研究的免疫分析,5)从少数族裔获取样本的行政程序,
优先分发样本,确保患者保密并遵守IRB
要求,并不断完善质量控制措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EVA COREY其他文献
EVA COREY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EVA COREY', 18)}}的其他基金
Exploring high-does testosterone as a potential treatment for abiraterone-resistant prostate cancer
探索高剂量睾酮作为阿比特龙耐药性前列腺癌的潜在治疗方法
- 批准号:
9095803 - 财政年份:2016
- 资助金额:
$ 17.44万 - 项目类别:
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling
Nemo 样激酶在 CaP 中的作用及其对雄激素受体信号传导的影响
- 批准号:
7494612 - 财政年份:2007
- 资助金额:
$ 17.44万 - 项目类别:
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling
Nemo 样激酶在 CaP 中的作用及其对雄激素受体信号传导的影响
- 批准号:
7315784 - 财政年份:2007
- 资助金额:
$ 17.44万 - 项目类别:
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling
Nemo 样激酶在 CaP 中的作用及其对雄激素受体信号传导的影响
- 批准号:
7908799 - 财政年份:2007
- 资助金额:
$ 17.44万 - 项目类别:
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling
Nemo 样激酶在 CaP 中的作用及其对雄激素受体信号传导的影响
- 批准号:
7691373 - 财政年份:2007
- 资助金额:
$ 17.44万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 17.44万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 17.44万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 17.44万 - 项目类别:














{{item.name}}会员




